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Abstract: We present an ex vivo study of temporally and spectrally 
resolved autofluorescence in a total of 47 endoscopic excision 
biopsy/resection specimens from colon, using pulsed excitation laser 
sources operating at wavelengths of 375 nm and 435 nm. A paired analysis 
of normal and neoplastic (adenomatous polyp) tissue specimens obtained 
from the same patient yielded a significant difference in the mean spectrally 
averaged autofluorescence lifetime −570 ± 740 ps (p = 0.021, n = 12). We 
also investigated the fluorescence signature of non-neoplastic polyps (n = 6) 
and inflammatory bowel disease (n = 4) compared to normal tissue in a 
small number of specimens. 
©201 Optical Society of America 
OCIS codes: (170.3650) Lifetime-based sensing; (300.6500) Spectroscopy, time-resolved; 
(300.6540) Spectroscopy, ultraviolet; (300.6550) Spectroscopy, visible; (120.3890) Medical 
optics instrumentation; (170.2680) Gastrointestinal. 
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1. Introduction 
Neoplasms of the gastrointestinal (GI) tract account for approximately a quarter of worldwide 
cancer mortality, equivalent to an incidence of about 2 million new cases each year [1, 2]. 
Prevention is based on early detection and excision of premalignant lesions (e.g. dysplasia, 
adenomas) and early stage cancers during endoscopic examination. This significantly 
increases patient survival while reducing disease progression and direct medical costs [3]. 
However, early stage lesions are often invisible or difficult to visualize under inspection with 
white light endoscopy (WLE) alone. In addition, it is often difficult to distinguish between 
benign and early or premalignant lesions, such as between inflammatory disorders and 
adenomas. This difficulty is currently overcome through taking a tissue biopsy specimen that 
is subsequently processed and assessed by a histopathologist. Neoplastic polyps are of 
particular clinical significance because of their established role in the stepwise process that 
results in colorectal cancer (the adenoma-carcinoma sequence) [4]. However, macroscopic 
discrimination between neoplastic polyps (consisting of adenomas with low grade or high 
grade dysplasia, and carcinomas) and non-neoplastic polyps (e.g. hyperplastic, inflammatory 
pseudopolyps, hamartomas) during WLE is extremely difficult. Therefore all polyps are 
removed when detected unless there is a clinical reason to delay the endoscopic resection and, 
following the current clinical best practice in GI endoscopy for tissue abnormalities, are 
biopsied or excised and sent for histological assessment and interpretation. This leads to 
unnecessary removal of benign lesions and a considerable number of tissue biopsies, which 
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are a significant burden on the healthcare system [5] and can be coupled with a low diagnostic 
yield [6, 7]. 
A non-invasive method of diagnosis could remove the need for physical biopsy and 
provide improvements in diagnostic accuracy for a number of diseases. Although several 
novel imaging techniques that can be operated in conjunction with standard WLE have 
recently become available in the clinical setting – such as narrow-band imaging (NBI) [8], 
autofluorescence imaging (AFI) [9] and more recently confocal endomicroscopy (CLE) [10, 
11] – there is still no red flag technique for detection of GI premalignant lesions that can 
progress into cancer. Furthermore, there is currently no technology that can reliably indicate 
when it is appropriate not to biopsy. As a result, despite the use of advanced imaging, in most 
cases multiple biopsies are still required to confirm or reject the endoscopic diagnosis. 
Various other optical approaches are being investigated for their potential to provide an in 
vivo label-free “optical biopsy” to aid diagnosis of GI disease, with the ultimate aim of 
allowing clinicians to avoid multiple unnecessary and/or random biopsies and instead permit 
targeting of both biopsies and resections. These include point probe-based diffuse reflectance 
spectroscopy [12–14], which has been applied to in vivo detection of dysplasia in Barrett’s 
esophagus (BE) [15] and to ex vivo surgical specimens of colon cancer [16], and Raman 
spectroscopy [17], which has recently been applied in a large study of 305 patients [18]. In 
this work we chose to focus on autofluorescence (AF) spectroscopy and lifetime 
measurements as they can be extended from point-based measurements to wide-field imaging 
once the spectroscopic features presenting the greatest contrast between normal and diseased 
tissue have been identified. 
Tissue autofluorescence arises from intracellular and extracellular endogenous 
fluorophores, such as collagen, elastin, pyridine nucleotides and flavins. The fluorescence 
signatures of these substances – along with their local distributions – have the ability to report 
on tissue disease state [19]. Further information can be obtained from the autofluorescence 
excitation and emission spectra [19, 20] and the decay rate (or fluorescence lifetime) [21–26]. 
A number of previous studies have investigated differences in autofluorescence emission 
spectra between healthy and diseased colonic tissue. Such investigations have demonstrated 
contrast in a variety of tissue types including: between normal tissue and adenomatous (i.e. 
neoplastic) polyps ex vivo [27–29]; between normal tissue and adenomas in vivo [30]; 
between normal tissue or hyperplastic polyps and adenomas [31]; between hyperplastic 
polyps and adenomas [32, 33]; and between all three of the above tissue groups [34]. Cancers 
in the upper GI tract (esophagus and stomach) have also been investigated [35–37]. In 
addition to point measurements of autofluorescence emission spectra, there have also been a 
number of applications of AFI modalities to the study of GI tissue [38–41]. AFI has been 
combined with high-definition videoendoscopy (HDE) [42] and also with NBI in so-called 
“trimodal imaging”, which has been applied to the study of Barrett's neoplasia [43]. However, 
none of the currently available techniques has been able to provide a clinical red flag 
technique for rapid and reliable detection of early changes of disease and it is interesting to 
investigate further sources of spectroscopic contrast such as autofluorescence lifetime (AFL). 
Ideally such a clinical technique should be able to survey wide areas of tissue for screening as 
well as offering the ability to obtain detailed information at specific points of interest. 
Time-resolved point-probe spectroscopy instrumentation has been developed by a number 
of groups [21, 44–47]. Time-resolved autofluorescence spectroscopy in the GI tract was 
pioneered by Mycek et al., whose in vivo study [21] on 24 polyps (13 adenomas, 11 non-
adenomas) from 17 patients using an excitation wavelength of 337 nm and detection in the 
range 530-570 nm demonstrated shorter average lifetimes for neoplastic polyps (adenomas) 
compared to non-neoplastic polyps (9300 ± 400 ps vs. 10500 ± 700 ps). In work by Li et al. 
in ex vivo tissue, longer AF lifetimes were found in cancerous colonic tissues using excitation 
at 397 nm and detecting at 635 nm compared to normal colon (18,450 vs. 4320 ps). This was 
attributed to the contribution of protoporphyrin IX (PpIX), which is known to both 
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accumulate in neoplasia and to have a long fluorescence lifetime [48]. Pfefer et al. [46] used 
excitation wavelengths of 337 and 400 nm and compared measurements of fluorescence 
emission spectra and fluorescence decay profiles acquired at 550 nm in vivo in 37 patients 
undergoing routine endoscopic surveillance for BE. In this study time-resolved fluorescence 
was unable to achieve sensitivity and specificity values above 60% for discriminating high 
risk (carcinoma, high grade dysplasia) from low risk (low grade dysplasia, non-dysplastic or 
indefinite for dysplasia) tissue, while moderate overall accuracy was achieved using steady-
state fluorescence only. 
To date, fluorescence lifetime imaging (FLIM) has only been applied to ex vivo studies of 
GI tissue. Mizeret et al. reported an increased fluorescence lifetime of an ex vivo human oral 
carcinoma compared to its surrounding uninvolved tissue [49] using frequency domain FLIM 
with 417 nm excitation with an argon ion laser-pumped dye laser and an emission detection 
band from 470 nm to 650 nm. Subsequently a more extensive study utilizing wide-field time-
gated FLIM with 355 nm excitation from a frequency-tripled Nd:YVO4 laser demonstrated a 
statistically significant increase in the fluorescence lifetime of invasive colonic 
adenocarcinomas (16 specimens) relative to the surrounding healthy tissue, while a decrease 
in fluorescence lifetime was observed in two serrated adenomas with focal high grade 
dysplasia [50]. 
The studies outlined above have motivated us to develop and evaluate instrumentation 
exploiting spectral and lifetime readouts of autofluorescence to contrast healthy and diseased 
GI tissue autofluorescence, in particular for colonic polyps. We have worked to develop 
compact and portable instrumentation utilizing picosecond gain-switched diode lasers 
operating at 20 MHz and are particularly interested to compare autofluorescence readouts 
with ultraviolet (375 nm) and blue (435 nm) excitation, noting the advantages of lower 
photodamage/phototoxicity, instrument background fluorescence and attenuation for longer 
wavelength excitation. In this study we are using point spectroscopy and integrating all spatial 
information to provide spectral and temporal resolution to higher precision than is practical 
when imaging. The resulting clinical spectroscopic data will then be used to guide the 
development of new clinical FLIM-based endoscopes intended to rapidly screen large areas of 
GI tissue. Here we describe a clinical study of colonic tissue that has been freshly 
biopsied/resected from patients undergoing endoscopy using a fiber-optic probe-based 
instrument with excitation at 375 nm and 435 nm and detection of the autofluorescence using 
a time-resolved fluorescence spectrometer. 
2. Materials and methods 
2.1 Patient enrolment 
A total of 47 endoscopic samples from different regions of colon were collected from 17 
patients undergoing colonoscopy. Each of these samples was then studied with the point-
probe system described below. All samples were submitted for histopathology following the 
optical measurements. Normal tissue, colonic polyps and inflammatory bowel disease (IBD) 
were investigated. 
Patients who participated in the research were recruited by the clinical team and gave their 
informed consent to participate. The study was carried out with the approval of the National 
Research Ethics Service (REC reference number 09/H0706/28). 
2.3 Fluorescence lifetime spectroscopy (FLS) instrumentation 
The optical system, which is represented in Fig. 1, is similar to that described in references 
[25, 26] but has been adapted for clinical deployment. Two pulsed diode lasers were used as 
excitation sources with central emission wavelengths of 375 nm and 435 nm (LDH-P-C-375B 
and LDH-P-C-440B respectively, PicoQuant GmbH, Germany). Both lasers emit pulses of 
50-150 ps duration and were configured to operate at 20 MHz. The outputs from the two 
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lasers were first combined and then coupled into the fluorescence excitation channel of a 
custom-built optical fiber probe (FiberTech Optica, Canada). This custom fiber probe 
comprised 19 multimode optical fibers (all of 0.22 NA and 200 μm diameter), of which 3 
were used to deliver the laser excitation to the sample and 14 were used to collect the 
resulting fluorescence. Two fibers in the bundle were unused. 
The distal branch of the probe (common to all optical fibers) was 3 m in length. At the 
distal end of the probe the fibers were arranged as shown in the lower central inset of Fig. 1. 
A medical grade stainless steel distal ferrule – protruding in front of the fiber output face – 
ensured that the sample was kept at a fixed distance of 1.5 mm from the distal face of the 
fiber bundle. This resulted in the excitation lasers illuminating an area of tissue of 
approximately 0.9 mm2. A neutral density (ND 0.7) filter was placed in the path of the  
375 nm laser in order to limit the average optical power at the sample to 35 μW. A bandpass 
filter (Z440/20x, Chroma Technology, USA) was used to narrow the spectrum of the 435 nm 
laser, which provided a maximum average power of 200 μW at the sample. The outputs of the 
two laser sources were controlled via computer and used to illuminate the specimen 
sequentially. In the investigation presented here, each measurement consisted of 5 s 
fluorescence data acquisition with the 375 nm laser followed by 5 s of acquisition with the 
435 nm laser. This cycle was repeated 3 times and the total acquisition time was 
approximately 35 s. 
< 200 μW @ 435 nm

















Fig. 1. Optical configuration of the fiber-optic probe-based fluorescence lifetime spectroscopy 
system. Insets show the arrangement of the optical fibers in the custom fiber bundle at the 
distal end of the probe and at the output of the fluorescence detection branch of the proximal 
end of the probe. Cores shown in green are fluorescence detection fibers; fibers colored blue 
are used to deliver the laser excitation; the orange and red cores were unused in this study. 
The resulting fluorescence was collected by the 14 fluorescence detection fibers that relay 
the collected light to the fluorescence detection arm of the spectrofluorometer (left hand side 
of Fig. 1). The output from the collection fibers is imaged onto the input slit of a grating 
spectrometer (MS125 1/8m, Lot-Oriel, UK), which is attached to a 16 channel multi-anode 
photomultiplier tube (PMT) detector (PML-16-SPEC, Becker-Hickl GmbH, Germany). The 
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PMT was linked to a computer with a time correlated single photon counting (TCSPC) card 
(SPC-730, Becker-Hickl, GmbH, Germany) and this allowed collection of fluorescence 
decays in 16 spectral channels spanning a wavelength range of 400-600 nm. At the fiber 
probe output, the 14 collection fibers were aligned vertically in order to maximize the 
coupling into the input slit of the spectrograph (see inset on left of Fig. 1). A motorized filter 
wheel was placed between the fiber probe output and the grating spectrometer. This filter 
wheel contained two emission filters, E400LPv2 and E475LPv2 (Chroma Technology, USA), 
that were used in combination with the 375 and 435 nm excitation lasers respectively to 
ensure that no scattered laser radiation reached the PMT detector. All optical components 
were mounted on a 30 × 45 cm2 breadboard, and the breadboard and all electrical components 
were housed and enclosed within a compact (182 × 70 × 55 cm3) wheeled trolley. The entire 
system is controlled through software written in LabVIEW 7.1 (National Instruments, USA). 
The optical fiber was designed such that it can be sterilized for future in vivo clinical 
measurements. 
In order to analyze the raw fluorescence data it was necessary to determine the 
wavelength range collected by each PMT element and to determine its relative sensitivity. 
This was performed in an identical manner to that described in references [25, 26]. First, the 
distal end of the fiber probe was illuminated with white light passed through a calibrated 
monochromator, which allowed the spectral center and bandwidth of each detection channel 
to be determined. Second, the relative sensitivity of each PMT element was found by 
recording the emission from a calibrated white light source (LS-1-CAL, Ocean Optics, The 
Netherlands) and this information was then used to correct the fluorescence intensity 
measured in each spectral channel. 
2.4 Experimental procedure 
During routine clinical endoscopy, pinch biopsy samples of any suspicious regions of tissue 
were taken with ‘jumbo’ biopsy forceps (Radial Jaw 3 LC forceps, Boston Scientific) and any 
superficial lesions (i.e. polyps) were removed with either a cold or a hot snare (Captivator 
single-use snares, Boston Scientific) according to standard practice in patient care. Polyps 
removed by hot snare polypectomy were sufficiently large (4-15 mm in diameter) that the 
area measured using the optical system was unaffected by any specimen heating. Where 
clinically possible, at least one biopsy of healthy tissue was also taken from each patient with 
a suspicious region and the healthy biopsy was taken as close as possible to the suspicious 
region. After completion of an endoscopic examination, any tissue samples obtained were 
immediately delivered to the adjacent spectroscopy room and measured with the fluorescence 
lifetime spectroscopy (FLS) system. 
All samples were measured within approximately 10 minutes of excision. Once removed, 
the biopsy samples or excised polyps were carefully teased onto gauze with sterile disposable 
tweezers, keeping the mucosal surface facing upward. All samples were washed gently by 
dripping Hanks' Balanced Salt Solution (HBSS) onto them. The distal tip of the optical fiber 
probe was then placed en face in contact with the sample and data acquisition was performed 
as described in the previous section. To ensure that the sample was not damaged by 
mechanical stress and to simulate in vivo probing, the distal end of the probe was held by 
hand, exerting constant gentle pressure throughout the measurements. There were no visible 
changes in the texture or appearance of the samples over the duration of the measurements 
and the sample thickness always remained consistent (compared to the original condition). 
Following measurements with the FLS system, all tissue samples were sent for 
histopathology where hematoxylin and eosin (H&E) stained tissue sections were reviewed by 
an experienced histopathologist (GWS). Each sample was assigned a unique number for 
identification purposes and the characteristics of the specimens investigated in this study are 
summarized in Table 1. 
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Table 1. Summary showing the clinical diagnoses of all the ex vivo samples investigated 
with the endoscopic spectrometer 
Tissue type Number of samples
Endoscopic diagnosis Histological diagnosis  
Colonic polyps 12x tubular adenomas with LGD 22 
 2x mixed hyperplastic adenomatous polyp with 
LGD 
 
 2x hyperplastic polyp  
 1x serrated polyp  
 3x inflammatory polyp  
 1x nonspecific reactive changes  
 1x normal colonic mucosa  
IBD 1x active chronic inflammation 6 
 2x severe chronic ulcerative colitis  
 2x moderate chronic colitis  
 1x basal inflammation  
Total number of diseased tissue 
measurements 
 28 
Normal colon tissue 18x normal colonic mucosa 19 
 1x active chronic inflammation  
Total number of measurements  47 
LGD, low grade dysplasia; IBD, inflammatory bowel disease. 
3. Data analysis 
3.1 Exponential fitting of autofluorescence decay profiles 
Autofluorescence from biological tissue typically exhibits a complex exponential decay 
profile as tissue contains several fluorescent species, each with a number of possible states 
(e.g. oxidized/reduced and free/protein bound). Thus, it is common practice to fit a multi-
exponential decay model to the recorded tissue fluorescence data. With an average of 2 × 105 
photons collected in each spectrally resolved decay profile, we chose to fit to a double 
exponential model given by Eq. (1), where τ1 and τ2 are the two lifetimes, and a1 and a2 are 
two pre-exponential amplitudes. 
 1 2
1 2
( ) exp expt tI t a a
τ τ
   
− −
= +      
 (1) 
The average reduced chi-squared produced by this fit model was 1.3 for 375 nm excitation 
and 2.6 for 435 nm excitation indicating that this model provides a reasonable fit to the data. 
More complex decay models, e.g. a triple exponential decay model, would provide better fits 
and lower reduced chi-squared values and have previously been used when analyzing lifetime 
data of biological tissue AF. However, the improved fit is often only the result of the higher 
number of fitting parameters used and it is no more realistic to assume the presence of 3 
mono-exponentially decaying fluorophores (or a single fluorophore with 3 discrete decay 
constants) than it is to assume the presence of one or two fluorophores. Because fitting three 
#194923 - $15.00 USD Received 31 Jul 2013; revised 11 Oct 2013; accepted 26 Nov 2013; published 16 Jan 2014
(C) 2014 OSA 1 February 2014 | Vol. 5,  No. 2 | DOI:10.1364/BOE.5.000515 | BIOMEDICAL OPTICS EXPRESS  523
or more exponential decays is more vulnerable to noise artifacts and requires a significantly 
greater number of detected photons than we were able to collect, we believe that using a 
double exponential decay model to parameterize the AF decay curves is a useful approach to 
investigate for contrast between different tissues. Other arbitrary complex models, e.g. based 
on Laguerre polynomial fits [51] could also provide empirically useful data. 
Reflected light temporal instrument response functions (IRFs) were recorded for each 
PMT channel by placing a diffusely reflecting sample at a short distance (~10 cm) from the 
distal end of the point-probe and then adjusting the angle of the grating in the spectrometer to 
direct light onto each PMT element in sequence. To account for the temporal shift of the IRF 
with respect to the data, a temporal offset fit parameter was included in the fluorescence 
decay analysis. 
3.2 Fluorescence data analysis 
Having fitted the fluorescence decay profiles according to Eq. (1), we calculated the mean 
fluorescence lifetime (τmean) in each spectral channel. This was achieved as shown in Eq. (2). 
 
2 2
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For each measurement, the variation in the mean lifetime was investigated as a function of 
emission wavelength. To summarize the fluorescence lifetime data from each sample in a 
simple manner, we then calculated a spectrally-averaged fluorescence lifetime for each 
measurement by averaging the spectrally resolved mean lifetime values and weighting the 




















τ is the spectrally averaged mean lifetime, n is the number of spectral channels 
included in the average and Ii and τi are respectively the total number of photons and mean 
lifetime recorded in each of the spectral detection channels. For 375 nm excitation, the 
spectrally averaged mean lifetime was calculated over the range 418-582 nm, excluding the 
first and last spectral channels owing to the weak signal and poor decay fitting in these 
channels. For 435 nm excitation, the spectrally averaged mean lifetime was calculated over 
channels 7-15 (481-582 nm) for the same reason. Following the initial analysis, we observed 
that the greatest lifetime contrast with 375 nm excitation for IBD was observed in spectral 
channels 8-13 (494-556 nm) and we therefore calculated a 2nd spectrally averaged mean 
lifetime over this narrower range. 
For each lesion, the difference between its spectrally averaged mean lifetime and that of a 
neighboring healthy tissue sample (excised from the same patient) was calculated 
(i.e. lesion normalτ τ τΔ = − ) in order to investigate the diagnostic potential of the fluorescence 
lifetime data, noting that this paired analysis of the fluorescence lifetime avoids the impact of 
inter-patient variation in the fluorescence lifetimes measured for normal tissue. The spectral 
properties of the samples were also investigated using their fluorescence emission spectra 
where the area under the fluorescence emission spectrum was normalized to unity. The mean 
fluorescence emission wavelength was also calculated for each sample and for each excitation 
wavelength. Finally, Wilcoxon signed rank tests were performed on all sets of spectrally 
averaged lifetime or mean emission wavelength shifts in order to test for statistically 
significant differences between healthy and diseased tissue. In all cases, the null hypothesis 
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being tested was that the measured lifetime or wavelength shifts come from a continuous, 
symmetric distribution with zero median. 
4. Results 
The analysis was performed using the histological diagnosis for each sample as the gold 
standard. Samples were excluded if microscopic analysis revealed normal large bowel 
mucosa in clinically abnormal samples or histological abnormalities in clinically normal 
specimens. 
4.1 Normal tissue characterization 
In the first part of our study we investigated the measured fluorescence emission spectra and 
fluorescence lifetimes in histologically normal tissue. Figures 2(a) and 2(b) show exemplar 
histological H&E stained sections of normal colon from a patient diagnosed with a polyp (a) 
and IBD (b), where a regular crypt architecture can be seen, including numerous mucin rich 
goblet cells assorted around the inner rim of the crypt openings (green arrowheads). Figures 
2(c) and 2(d) show the mean fluorescence emission spectra from histologically normal colon 
obtained from patients diagnosed with a polyp or IBD. Normal colon from patients with IBD 
shows a slight shift to shorter emission wavelengths for 375 nm excitation compared to 
normal colon obtained from patients diagnosed with a polyp. There is also a slight shift to 
longer emission wavelengths for excitation at 435 nm. However, the change in mean emission 
wavelength was not found to be statistically significant for either excitation wavelength. The 
fluorescence lifetime recorded in each spectral channel for normal tissue from patients 
diagnosed with a polyp and IBD is plotted in Figs. 2(e) and 2(f). For 375 nm excitation, the 
mean fluorescence lifetime varies slightly with emission wavelength, with a maximum at an 
emission wavelength of around  
500 nm. For 435 nm excitation, the mean fluorescence lifetime is more consistent with 
emission wavelength. In order to get a better overview of the fluorescence lifetime, we 
calculated the spectrally averaged fluorescence lifetimes – see Fig. 2(g) – which shows that 
there is a higher mean fluorescence lifetime for normal tissue with 435 nm excitation for 
patients diagnosed with a polyp compared to patients diagnosed with IBD. However, this shift 
was not found to be statistically significant by two-way ANOVA (normal data was tested 
according to both diagnosis (p = 0.11) and region (p = 0.30), null hypothesis that all groups 
are drawn from populations with the same mean). 
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Fig. 2. Summary of results from normal tissues grouped according to whether the patient was 
diagnosed with a polyp (n = 13) or IBD (n = 4). (a & b) Exemplar H&E stained histological 
sections of a biopsy sample of normal colon from a patient diagnosed with a polyp (a) and IBD 
(b). Scale bar represents 100 μm, see text for description of arrowheads. (c) & (d) show the 
mean fluorescence emission spectra obtained with 375 and 435 nm excitation, respectively. (e) 
& (f) show the spectrally resolved fluorescence lifetimes for 375 and 435 nm excitation, 
respectively. (g) shows the spectrally averaged mean fluorescence lifetimes for both groups 
and for both excitation wavelengths. The error bars represent ± 1 standard deviation in all 
panels. 
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We also grouped the fluorescence lifetime data from all histologically normal samples 
according to the region of colon from which they were obtained. Figures 3(a) and 3(b) show a 
slight blue shift in the fluorescence emission spectrum for the two specimens obtained from 
the rectum for 375 nm excitation, but this shift in mean emission wavelength was not found to 
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Fig. 3. Summary of results from normal tissues grouped according to the location that the 
specimen was taken from. The number of specimens in each group was: rectum (n = 2), left (n 
= 8), transverse (n = 5), right (n = 3). (a) & (b) show the mean fluorescence emission spectra 
obtained with 375 and 435 nm excitation respectively. (c) shows the spectrally averaged mean 
fluorescence lifetimes for both groups and for both excitation wavelengths. The error bars 
represent ± 1 standard deviation in all panels. 
The mean fluorescence lifetime obtained with 435 nm excitation from the two rectal 
specimens is longer than that obtained from the other three regions; see Fig. 3(c). As reported 
above, however, we performed 2-way ANOVA on the spectrally averaged mean fluorescence 
lifetimes from histologically normal colon grouped according to both diagnosis and region of 
colon and no statistically significant differences were obtained. 
4.2 Diseased vs. normal tissue 
Of the 22 clinically identified polyps (see Table 1), one was excluded as it was found to be 
normal by histopathology. The polyp specimens included in our analysis are summarized in 
Table 2. Where possible, at least one specimen of normal colon was obtained from all 
patients. 
4.2.1 Colonic polyps 
Figures 4(a) and 4(b) show exemplar histological H&E stained sections of (a) neoplastic and 
(b) non-neoplastic polyps, respectively. In neoplastic tissue (adenomatous polyp), the crypts 
appear displaced by large dense branching bands of interstitial space mostly free of cells. 
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Crypts are distorted and elongated (red asterisks), and significantly fewer goblet cells can be 
observed, which are now replaced by crowded elongated cells with large nuclei (red 
arrowheads). In non-neoplastic tissue (hyperplastic polyp), glands have a star-shaped lumen 
(green asterisks) – when seen in cross-sections – that is characteristic of these polyps. Crypts 
are straight, narrowed and hyperchromatic at the base. Nuclei are small, regular, round and 
with basal orientation with respect to the crypt lumen (green arrowheads) and dysplastic 
changes are not present. The basal membrane is also commonly thickened. 
Figures 4(c) and 4(d) show the normalized mean fluorescence spectra observed in normal 
colon tissue and in neoplastic (tubular adenomas with LGD and mixed hyperplastic 
adenomatous polyps) and non-neoplastic (hyperplastic and inflammatory) colonic polyps for 
both excitation wavelengths. These spectra overlap within the error bars and no statistically 
significant difference was obtained when comparing the mean fluorescence emission 
wavelength for either excitation wavelength. Figures 4(e) and 4(f) show the mean 
fluorescence lifetimes measured in each spectral channel for both 375 and 435 nm excitation. 
The mean fluorescence lifetimes for neoplastic polyps were shorter than those observed in 
normal tissue for both excitation wavelengths and this trend was observed in all spectral 
channels. The spectrally averaged mean fluorescence lifetime (weighted according to the 
intensity recorded in each spectral channel) for normal tissue, neoplastic and non-neoplastic 
polyps is shown in Fig. 4(g). 
As can be seen from the size of the error bars on the fluorescence lifetime measurements 
in Fig. 4, there is significant inter-patient variability in the measured mean fluorescence 
lifetime from both normal and diseased specimens. Therefore, in order to overcome this 
variability, we conducted a paired analysis by calculating the difference in spectrally 
averaged mean fluorescence lifetime between normal and lesional specimens obtained from 
the same patient. This paired analysis was performed using a total of 30 specimens (see  
Table 2). 
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Fig. 4. Comparison of normal tissue versus neoplastic and non-neoplastic polyp specimens. (a) 
& (b) show exemplar H&E stained histological sections of (a) neoplastic (adenomatous polyp) 
and (b) non-neoplastic (hyperplastic polyp) polyps, respectively. Scale bar represents 100 μm, 
see text for description of arrowheads and asterisks. (c) & (d) show the mean fluorescence 
emission spectra obtained with 375 and 435 nm excitation, respectively. (e) & (f) show the 
spectrally resolved fluorescence lifetimes with 375 and 435 nm excitation, respectively. (g) 
shows the spectrally averaged mean fluorescence lifetimes for all three groups and for both 
excitation wavelengths. The error bars represent ± 1 standard deviation in all panels. 
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Table 2. Summary of colonic polyps included in study 
 Unpaired analysis Paired analysis 
No. of patients 12 11 
No. of polyps 21 18 
Neoplastic 15 12 
Non-neoplastic 6 6 
No. of normal specimens 13 12 
Three polyps obtained from one patient were excluded from the paired analysis as it was 
not clinically possible to obtain a normal specimen in this patient. In the one patient where 
two normal specimens were obtained, the lesional specimens were compared to the 
anatomically closest normal specimen. 
For each normal-lesion pair, both the shift in mean fluorescence emission wavelength and 
the shift in spectrally averaged mean fluorescence lifetime were calculated for both excitation 
wavelengths. The measured shift in mean fluorescence emission wavelength was not found to 
be statistically significant for either excitation wavelength. Figure 5 shows the shift in the 
spectrally averaged fluorescence lifetime (Δτ) for each normal-lesion pair. The mean values 
calculated over all pairs for neoplastic polyps and non-neoplastic polyps are summarized in 
Table 3. 
Table 3. Spectrally averaged fluorescence lifetime shift for neoplastic and non-neoplastic 
polyps 
 Mean shift in spectrally averaged 
fluorescence lifetime of polyp compared 
to normal tissue from same or nearest 
region of colon (ps) 
Mean shift in spectrally averaged 
fluorescence lifetime of polyp 
compared to normal tissue from same 
region of colon (ps) 
Excitation 
wavelength 
375 nm 435 nm 375 nm 435 nm 
Neoplastic -230 ± 560 -570 ± 740 -310 ± 510 -690 ± 640 
  (p = 0.021)  (p = 0.0049) 
Non-neoplastic 25 ± 820 
−160 ± 780 −250 ± 680 −620 ± 400 
A Wilcoxon signed rank test was applied to all sets of paired difference values. The data 
obtained with 375 nm excitation showed no significant differences while the 435 nm excited 
data shows a statistically significant decrease in the fluorescence lifetime of neoplastic polyps 
with respect to healthy tissue (p = 0.021). We also found that the spectrally averaged 
difference in τ2 between neoplastic polyp and normal tissue for 435 nm excitation was 
statistically significant (Δτ2 = −690 ± 970 ps, p = 0.05). The difference in spectrally averaged 
mean lifetime shift between neoplastic and non-neoplastic polyps for 435 nm excitation was 
not found to be statistically significant (Wilcoxon rank sum test). 
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Fig. 5. Shift in the spectrally averaged mean fluorescence lifetime for (a) 375 nm and (b) 435 
nm excitation of neoplastic (red) and non-neoplastic polyp (green) specimens. Lifetime shifts 
are calculated using a measurement of normal tissue obtained from the same or nearest region 
of colon (paired analysis). 
Specimens 23, 33 and 34 correspond to patients where the normal sample was not taken 
from the same region of colon as the polyp. If these specimens are excluded from the analysis 
then for 435 nm excitation the shift in mean emission wavelength averaged over all neoplastic 
specimen pairs becomes 2.6 ± 3.1 nm (p = 0.019) and the shift in spectrally averaged mean 
lifetime averaged over all neoplastic specimen pairs becomes −690 ± 640 ps (p = 0.0049), see 
Table 3. The increase in mean emission wavelength at this excitation wavelength was found 
to be correlated with the decrease in fluorescence lifetime (R2 = 0.71). While the shift in 
spectrally averaged 435 nm excited mean fluorescence lifetime for non-neoplastic polyps 
decreased, it was not found to be statistically significant. 
4.2.2 Inflammatory bowel disease 
A total of 11 specimens (6 diseased and 5 normal) were measured from 5 patients with IBD. 
One normal and one IBD specimen (from different patients) were excluded because the 
histopathological assessment revealed no difference between the normal and the diseased 
samples. Therefore, we analyzed the numbers of specimens shown in Table 4. 
Table 4. Summary of IBD (inflammatory bowel disease) specimens included in the study, 
divided by type of analysis performed 
 Unpaired analysis Paired analysis 
No. of patients 5 3 
No. of IBD specimens 5 4 
No. of normal specimens 4 3 
Total No. of specimens 9 7 
Figures 6(a) and 6(b) show exemplar histological H&E stained sections of (a) normal 
colonic mucosa and (b) IBD tissue, respectively. Both samples were taken from the same 
patient affected by active distal ulcerative colitis. Regular crypt architecture can be seen in the 
uninflamed mucosa (Fig. 6(a)). In contrast, moderate chronic active inflammation with severe 
distortion of crypt architecture and prominent crypt abscesses with disruption of crypts and 
areas of crypt loss is observed in the inflamed tissue (red arrowheads in Fig. 6(b)). Goblet cell 
and mucin depletion with reactive atypia of the glandular epithelium is also seen compared to 
the healthy tissue. 
Figures 6(c) and 6(d) show the emission spectra obtained for normal and IBD specimens 
for both excitation wavelengths. For 375 nm excitation, the emission spectrum is shifted to 
the red for IBD specimens compared to normal, but the shift in mean emission wavelength 
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was not found to be statistically significant (p = 0.06). The spectrally resolved mean 
fluorescence lifetimes are shown in Figs. 6(e) and 6(f). With 375 nm excitation the mean 
fluorescence lifetime observed in IBD was longer than that of normal tissue in all spectral 
channels and this difference appeared to be greater for longer emission wavelengths. Thus, 
for this excitation wavelength we calculated the spectrally averaged mean fluorescence 
lifetime over a reduced spectral emission range of 494-556 nm as this gave the greatest 































































































































































































Fig. 6. Comparison of normal tissue and IBD specimens. (a) & (b) show an exemplar H&E 
stained histological sections of biopsy samples obtained from one patient of (a) normal colonic 
mucosa and (b) IBD tissue (ulcerative colitis) respectively. Scale bar represents 100 μm, see 
text for description of arrowheads. (c) & (d) show the mean normalized fluorescence emission 
spectra obtained with 375 nm and 435 nm excitation, respectively. (e) & (f) show the 
spectrally resolved mean fluorescence lifetimes with 375 nm and 435 nm excitation, 
respectively. (g) shows the spectrally averaged mean fluorescence lifetime for both groups and 
for both excitation wavelengths. The spectrally averaged mean fluorescence lifetime for 375 
nm excitation was obtained using the emission spectral range 494-556 nm. The error bars 
represent ± 1 standard deviation in all panels. 
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Figure 7 shows the shift observed in the spectrally averaged mean fluorescence lifetime 
for each IBD sample investigated measured with respect to normal tissue obtained from the 
same patient (paired analysis). With 375 nm excitation, the fluorescence lifetimes of all four 
IBD samples are longer than those of the nearby normal colon tissue (mean Δτ = 983 ±  
289 ps) but this shift was not found to be statistically significant using the Wilcoxon signed 
rank test (p = 0.125). We also investigated the paired shift in mean fluorescence emission 
wavelength between IBD and healthy tissue (mean Δλ = 6.9 ± 6.6 nm, p = 0.25), which was 
also not statistically significant. The lack of statistical significance is due to the relatively 
large standard deviations on the spectral and lifetime shifts and the small number of 
measurements made for this disease type. Further measurements would be needed to establish 
if the trends observed are significant. It is also worth noting that the shifts in the mean 
fluorescence emission wavelength and the spectrally averaged mean fluorescence lifetime 
were correlated (R2 = 0.90). Additionally, the relative error for the mean shift in spectrally 
averaged mean lifetime was a factor of 3.4 times smaller than the relative error for the mean 












































































Fig. 7. Bar graphs showing the shift in the spectrally averaged mean fluorescence lifetime 
observed in all IBD samples relative to a sample of healthy tissue from the same patient. (a) & 
(b) show lifetime shifts obtained with 375 nm and 435 nm excitation respectively. The lifetime 
shift for 375 nm excitation was obtained using the spectrally averaged mean lifetime calculated 
over the emission spectral range 494-556 nm. 
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Fig. 8. Summary of all measured shifts in mean fluorescence emission wavelength and 
spectrally averaged mean fluorescence lifetime for (a) 375 nm and (b) 435 nm excitation 
wavelengths. The lifetime shift for 375 nm excitation was obtained using the spectrally 
averaged mean lifetime calculated over the emission spectral range 494-556 nm for all points. 
Figure 8 shows summary plots of all paired measurements of shift in mean fluorescence 
lifetime against shift in mean emission wavelength for both excitation wavelengths. Paired 
measurements between two regions of normal tissue would be expected to cluster around the 
origin. However, it was not possible to obtain such specimens in this study and it was 
therefore not possible to compare the distribution of normal-normal tissue measurements with 
those obtained from normal-diseased tissue. Polyp specimens tend to show a decrease in the 
435 nm excited spectrally averaged fluorescence lifetime and IBD specimens show an 
increase in the 375 nm excited spectrally averaged fluorescence lifetime as already discussed 
in the figures above. The red line in Fig. 8(b) indicates a potential decision line between 
neoplastic and non-neoplastic polyps, which in this case provides a sensitivity/specificity of 
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75%/83%. This discrimination mainly makes use of the shift in fluorescence emission 
wavelength rather than the shift in fluorescence lifetime. 
5. Discussion 
For “normal” colon (Figs. 2(a) and 2(b) and Fig. 6(a)), our study found no statistically 
significant variation for either of the excitation wavelengths employed in the mean 
fluorescence emission wavelength or spectrally averaged mean fluorescence lifetime between 
tissue from patients presenting polyps or IBD or between tissues from different regions of the 
colon. We would have expected to see contrast based on the known variations in the structure 
and composition of these tissues, as segmental variations in normal colon morphology from 
proximal to distal segments – following the sequence caecum, right colon, transverse colon, 
left colon, rectum – are well known [52]. From the caecum to the rectum there is a gradual 
significant decrease in the diameter of the crypts, the number of crypts per unit area and the 
inner intestinal circumference. There is also an increase in thickness of the mucosa from the 
caecum (0.5 mm) to the rectum (1 mm). Furthermore, crypts are deeper in the rectum and 
sigmoid colon than they are in the proximal part of the colon. In addition, it must also be 
considered that patients with IBD have been variably subjected to medical therapy with 
steroids, immunomodulators, antibiotics and biologics, which might be responsible for further 
changes in the mucosal layer thickness/permeability across the entire colon compared to that 
of untreated patients (i.e. those with polyps). We did observe small changes in emission 
spectral profile and fluorescence lifetime for these different tissue types but these differences 
were not statistically significant. This is likely to be due to the relatively small number of 
specimens in each group. A study on a larger number of specimens would be needed to see if 
this is true. 
Neoplastic polyps are characterized by the presence of epithelial dysplasia and are 
precursors to colorectal cancer. The histological hallmarks of dysplasia include: the presence 
of hyperchromatic, elongated and stratified nuclei; highly disorganized architecture; abundant 
and unregulated epithelial proliferation; mucosal thickening; crypt enlargement; “back to 
back” aspect of dysplastic cells; lamina propria displacement; a reduction in the number of 
goblet cells; and aberrant crowded tubular or tubulovillous crypts lined by elongated cigar-
shaped cells with narrowing of the crypt lumen (Fig. 4(a)). These changes are normally most 
pronounced at the head of the polyp (intraluminal protruded portion). The increase in cell 
density and collagen content in these tissues may cause an increase in optical scattering and 
the increase in thickness may reduce the contribution of fluorescence signal from lower tissue 
layers (lamina propria and basal membrane) [53, 54]. Multiphoton microscopy has been used 
to show that dysplastic epithelium typically displays a higher redox ratio due to increased 
cellular metabolism [55]. The other expected change between normal colon and polyps is the 
hemoglobin concentration, which is on average 6 times higher than in normal mucosa [14]. 
Non-neoplastic polyps can be divided into hyperplastic and inflammatory. Hyperplastic 
polyps consist - when seen in cross-section - of piled up goblet cells creating an uneven 
surface architecture (Fig. 4(b)). The most distinctive histological features of inflammatory 
polyps are hyperplasia of the epithelium and of the lamina propria, mixed inflammatory 
infiltrates, and erosion. 
For 375 nm excitation we expect the dominant tissue fluorophores within the mucosa to 
be collagen types I-IV and intracellular nicotinamide adenine dinucleotide phosphate 
(NAD(P)H). Collagen type IV is primarily found in the linings surrounding the colonic crypts 
(basal membranes), whereas collagen types I-III are predominant in the stroma of the lamina 
propria [56, 57]. Collagen fluorescence is particularly complex and a range of values are 
reported in the literature, e.g [58, 59], and recent measurements of type II collagen obtained 
with an instrument similar to that used here showed a peak emission wavelength of  
390-430 nm and a mean fluorescence lifetime of approximately 10 ns for excitation at 355 nm 
[60]. NADH has a peak emission wavelength of 460 nm and a mean fluorescence lifetime of 
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440 ps in its free state [61] and longer decay components typically in the range ~2-2.5 ns 
when protein bound [62]. Our results show a peak fluorescence emission wavelength of  
470 nm that is broadly consistent with the fluorescent signal being a combination of collagen 
and NAD(P)H fluorescence. The fluorescence lifetime measured in this study in the range  
3-3.5 ns is also broadly consistent with a combination of the longer decay components found 
for collagen and those of free and protein-bound NAD(P)H. 
In IBD, the intestine is chronically infiltrated by inflammatory cells and in the presence of 
active disease the epithelium can be severely damaged and frayed (goblet cell and mucin 
depletion), leaving large exposed areas of underlying connective tissue (Fig. 6(b)). In 
addition, lymphocytes can cause degradation of collagen [63], the crypts are damaged by 
intense infiltration of neutrophils (crypt abscesses) and crypt architecture appears distorted. 
Crypts are unequally spaced and surrounded by an interstitial matrix fully infiltrated by 
inflammatory cells (neutrophils, lymphocytes and plasma cells). Erythrocytes extravasated 
from capillaries of the lamina propria may also be present. Loosening of the interstitial space 
and small crypt openings are also observed. Endoscopically, the mucosa is grossly denuded, 
with often active bleeding on the surface. 
The increase in exposed connective tissue would be expected to increase the contribution 
of mucosal collagen fluorescence measured by the fiber-probe for excitation at 375 nm and 
therefore to produce a corresponding increase in the mean fluorescence lifetime (due to the 
longer mean fluorescence lifetime of collagen compared to NAD(P)H). We do see an increase 
in the mean fluorescence lifetime observed for IBD, as shown in Fig. 6(g), although this was 
not found to be statistically significant. However, an increase in the contribution of collagen 
fluorescence to the signal might also be expected to decrease the mean fluorescence emission 
wavelength but here we observed an increase - although this was not statistically significant. 
In IBD, the metabolic pathway is still not completely understood due to differences in 
disease states (acute, chronic, active, quiescent) and the wide variation of both metabolic and 
structural factors involved, such as cytokines secretion, epithelia destruction and regeneration, 
inflammatory cells infiltrates, autophagy, etc [64, 65]. It is therefore difficult to predict the 
changes in intracellular AF. Reduced epithelial redox ratios have previously been measured in 
inflammatory cervical epithelial tissues [63]. Another factor to consider is that the mean 
penetration depth of light in IBD tissue may be affected by the typically decreased 
concentration of hemoglobin, which would occur for both diseased and normal samples taken 
from the same patient given the systemic nature of anemia. 
For 435 nm excitation we expect the dominant fluorescence signal to be due to 
intracellular flavins within the mucosa with perhaps some additional signal from mucosal 
collagen, which can be excited at this wavelength [66]. The fluorescence emission spectra 
peak measured in this study at ~530 nm is broadly consistent with the emission spectra of 
flavins [67] and collagen [66]. In a paired analysis of normal and lesional specimens obtained 
from the same region of colon, we found that 435 nm excitation of neoplastic colonic polyps 
provides a statistically significant difference in the spectrally averaged mean fluorescence 
lifetime (shorter) compared to healthy tissue. This shift in mean fluorescence lifetime was 
found to be correlated (R2 = 0.71) with a shift in mean emission wavelength. The changes in 
fluorescence emission spectrum and lifetime might be explained by changes in the ratio of 
free:protein-bound flavin fluorescence [68, 69] or by changes in the ratio of intracellular 
flavin fluorescence to collagen fluorescence. We also applied statistical tests to the difference 
between lesion and normal tissue for each of decay parameters derived from the double 
exponential analysis, i.e. τ1, τ2 and the initial fraction of fluorescence in the short decay 
component, a1/(a1 + a2), which were all spectrally averaged in the same way as the mean 
fluorescence lifetime. Of these parameters, only the paired difference in spectrally averaged τ2 
between neoplastic polyp and normal tissue for 435 nm excitation was found to be 
statistically significant. 
#194923 - $15.00 USD Received 31 Jul 2013; revised 11 Oct 2013; accepted 26 Nov 2013; published 16 Jan 2014
(C) 2014 OSA 1 February 2014 | Vol. 5,  No. 2 | DOI:10.1364/BOE.5.000515 | BIOMEDICAL OPTICS EXPRESS  536
To date there are relatively few reports of AFL studies in the colon. Only one study – by 
Mycek et al. [21] – has investigated single point measurements of AFL on colonic polyps at 
337 nm excitation. However, while this was the first study in the human colon that 
demonstrated differences in fluorescence lifetime decay between non-dysplastic and 
dysplastic tissue, it was mainly carried out to assess the ability of time-resolved AF 
spectroscopy in distinguishing between adenomatous and non-adenomatous polyps and no 
measurements from normal tissue were presented. Nevertheless, adenomas showed faster 
average decays than those of non-adenomas (9300 ± 400 ps vs. 10500 ± 700 ps), where non-
adenomas comprised 6 hyperplastic polyps, 3 mucosal prolapses, 1 lymphoid aggregate, and 
1 aberrant crypt focus. In the study presented here, we also observed shorter spectrally 
averaged decays for neoplastic compared to non-neoplastic polyps for either excitation 
wavelength although these differences were not statistically significant. We note that the 
shorter excitation wavelength (337 nm) used by Mycek et al. means that their work and our 
results presented should be compared with caution. 
Although we kept the time between tissue removal and autofluorescence measurements to 
below 10 minutes for all specimens, there are a number of potential changes that may occur to 
the tissue during this time. The blood volume and/or relative concentration of oxyhemoglobin 
may decrease and the tissue may experience geometrical changes post excision, e.g. 
shrinkages, tissue curling or crush artifacts and/or changes in thickness of the colonic mucosa 
layers caused by the biopsy forceps or diathermy [33, 70] which could affect the absorption of 
the excitation beam, the tissue volume sampled by our instrument and attenuation of the 
emitted fluorescence. Changes in tissue oxygenation could also affect the metabolic state of 
cells. These factors could all potentially impact the measured autofluorescence lifetimes. 
However, the measurement time for normal/diseased pairs in this study was always 
reasonably well-matched and it is likely that any change to ex vivo tissue fluorescence would 
affect all areas of a sample uniformly and so would be unlikely to alter the relative lifetime 
contrast between normal and neoplastic tissue [50]. 
We note that there are a few published studies of how AF signals can change following 
resection. AF in colonic tissue from intracellular fluorophores such as NAD(P)H has been 
reported to decay ex vivo over a time scale of 118 minutes due to tissue deoxygenation, while 
the AF from collagen and flavins remained relatively constant [33]. In addition, similar AF 
intensity and spectral line shapes to that of in vivo tissue have been reported for freshly 
excised tissue in a hamster cheek pouch model [71]. In a study of ischaemic mouse skin by 
Palero et al. [72] using spectrally resolved multiphoton microscopy, the change in 
fluorescence intensity was reported to increase by 71% compared to baseline over 
approximately one hour and the change in peak emission wavelength shifted from 456 nm to 
450 nm after 20 minutes. It is clear that caution should be exercised when trying to 
extrapolate ex vivo findings to what could be expected in vivo. Nonetheless, ex vivo 
measurements are a useful first step to investigating the contrast that is likely to be seen in 
vivo. 
6. Conclusions 
Optically-assisted diagnosis could be important for medical conditions where biopsies are still 
required to confirm and characterize the presence and stage of disease. One such example is 
colonic surveillance for proliferative or inflammatory diseases, where an optical biopsy could 
enable real-time diagnosis during endoscopy, thereby avoiding multiple and random 
unnecessary biopsies. Discrimination between dysplasia and inflammation is still one of the 
most important dilemmas in GI endoscopy. 
We have presented an ex vivo study of time-resolved autofluorescence spectra of freshly 
biopsied/removed colonic tissue samples collected from patients undergoing endoscopy as 
part of their clinical investigation. This was undertaken with a compact fiber-optic coupled 
time-resolved spectrofluorometer utilizing all-solid-state picosecond diode lasers. In a paired 
#194923 - $15.00 USD Received 31 Jul 2013; revised 11 Oct 2013; accepted 26 Nov 2013; published 16 Jan 2014
(C) 2014 OSA 1 February 2014 | Vol. 5,  No. 2 | DOI:10.1364/BOE.5.000515 | BIOMEDICAL OPTICS EXPRESS  537
analysis between normal tissue and neoplastic colonic polyps obtained from the same patient, 
the decrease in 435 nm excited spectrally averaged mean fluorescence lifetime measured over 
all patients was found to be statistically significant (mean Δτ = −570 ± 740 ps, n = 12, p = 
0.021). If we exclude one sample where it was not possible to obtain a normal sample from 
the same region of colon, then the level of statistical significance increases (mean Δτ = −690 
± 640 ps, n = 11, p = 0.0049) and the increase in mean emission wavelength also becomes 
statistically significant (mean Δλ = 2.6 ± 3.0 nm, n = 11, p = 0.019). The shift in spectrally 
averaged mean fluorescence lifetime was found to be correlated with the shift in emission 
spectrum (R2 = 0.71). While non-neoplastic polyps showed a mean difference in mean 
fluorescence lifetime of −620 ± 400 ps compared to normal tissue obtained from the same 
region of colon (n = 4), this was not found to be statistically significant for this small sample 
size. 
With respect to discriminating between inflammation and normal tissue, we note that 
there seemed to be an increase in autofluorescence lifetime for inflamed tissue (IBD) 
compared to normal tissue but the positive lifetime differences observed were not statistically 
significant for the small number (n = 4) of IBD specimens studied The increase in 375 nm 
excited fluorescence lifetime (mean Δτ = 983 ± 289 ps) was correlated (R2 = 0.90) with an 
increase in fluorescence emission wavelength (Δλ = 6.9 ± 6.6 nm). 
If the changes in mean autofluorescence lifetime and emission wavelength of 435 nm 
excited fluorescence are combined, then the discrimination of neoplastic from non-neoplastic 
polyps with a modest sensitivity/specificity of 75%/83% is achieved. Further work is required 
to see if this can be improved through the use of e.g. other excitation wavelengths, or 
combinations of fluorescence spectroscopy with other non-invasive optical techniques. 
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